Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial

American Heart Journal

Volumn 157, Issue 5, 2009, Pages 913-918

  Adabag, A Selcuk ^a,b,c   Mithani, Salima ^a,c   Al Aloul, Basel ^a,c   Collins, Dorothea ^d   Bertog, Stefan ^a,c   Bloomfield, Hanna E ^b,c  

^a Division of Cardiology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAPHY; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL ANALYSIS;

AGED; ANTILIPEMIC AGENTS; ATRIAL FIBRILLATION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GEMFIBROZIL; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 64349100428     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.02.015     Document Type: Article

References (26)

1. Hanna I.R., Heeke B., Bush H., et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3 (2006) 881-886
2. Kantharia B.K. Lipid lowering drugs: beyond lowering lipid levels to their influence on cardiac arrhythmias. Heart Rhythm 3 (2006) 887-888
3. Mitchell L.B., Powell J.L., Gillis A.M., et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmic Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 42 (2003) 81-87
4. De Sutter J., Tavernier R., De Buyzere M., et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
5. Young-Xu Y., Jabbour S., Goldberg R., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
6. Adabag A.S., Nelson D.B., Bloomfield H.E., et al. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 154 (2007) 1140-1145
7. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 (2003) 1343-1345
8. Ozaydin M., Varol E., Aslan S.M., et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97 (2006) 1490-1493
9. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
10. Diep Q.N., Benkirane K Amiri F., et al. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 36 (2004) 295-304
11. Kleemann R., Verschuren L., de Rooji B.J., et al. Evidence for anti-inflammatory activity of statins and PPAR alpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103 (2004) 4188-4194
12. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
13. Bloomfield H.E. The role of fibrates in a statin world. Arch Intern Med 166 (2006) 715-716
14. Rubins H.B., Robins S.J., Iwane M.K., et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 71 (1993) 45-52
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 3163-3170
16. Cox D.R. Regression models and life-tables. J R Stat Soc 34 (1972) 187-202
17. Pedersen O.D., Bagger H., Kober L., et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100 (1999) 376-380
18. Vermes E., Tardif J.C., Bourassa M.G., et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107 (2003) 2926-2931
19. Maggioni A.P., Latini R., Carson P.E., et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149 (2005) 548-557
20. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006) 1455-1461
21. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
22. Aviles R.J., Martin D.O., Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
23. Engelmann M.D., and Svendsen J.H. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26 (2005) 2083-2092
24. Shimano M., Tsuji Y Inden Y., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 5 (2008) 451-459
25. Wilson L.D., and Tsai C.T. Heart failure-related atrial fibrillation: a new model for a new prevention strategy?. Heart Rhythm 5 (2008) 460-461
26. Steg P.G., López-Sendón J., Lopez de Sa E., et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 167 (2007) 68-73